Clinical Trials Logo

Clinical Trial Summary

Background:

Sj(SqrRoot)(Delta)gren s Syndrome (SS) is an autoimmune disease that affects the glands that produce saliva and tears, causing dry eyes and dry mouth.

Researchers do not know the exact cause of SS, but they believe that it may be caused by abnormalities in the autonomic nervous system (ANS) that stimulate these glands.

Objectives:

To better understand ANS function in patients with SS.

To compare information about ANS function in healthy individuals and in patients with SS.

Eligibility:

Patients with Sj(SqrRoot)(Delta)gren s Syndrome who are 18 years of age and older, and who are not pregnant or breastfeeding.

Participants will be asked to taper or discontinue the use of certain medications or dietary supplements before the ANS testing.

Participants must be willing to discontinue the use of alcohol and tobacco 24 hours prior to testing.

Design:

The study will require one inpatient admission and/or outpatient visits to the NIH Clinical Center.

The following tests and procedures will be performed:

- Saliva, tear, and sweat production measurements to evaluate the function of glands.

- Testing of changes to the cardiovascular system, including blood pressure and blood flow testing, and an electrocardiogram designed to evaluate hemodynamic changes controlled by the ANS.

- Testing of changes to the gastrointestinal system, including a swallowing assessment study, barium swallow study, and gastric emptying study designed to evaluate gastrointestinal function controlled by the ANS.

- Tests to evaluate the ANS function in response to certain drugs (edrophonium, glucagon and acetylcholine).

- Self-reported questionnaire on ANS function and emotional/psychological well-being.

Additional procedures and tests may include the following:

- Blood samples.

- Optional skin biopsy to study sweat glands and nerve supply of the skin.


Clinical Trial Description

Sj(SqrRoot)(Delta)gren s syndrome (SjS) is a systemic exocrinopathy that affects as high as 5 percent of the population. It is manifested predominantly as dry eyes, dry mouth, and fatigue. The exocrinopathy can be encountered alone (primary SjS) in approximately one half of the patients or in the presence of another autoimmune disorder such as rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis (secondary SjS). The most widely accepted classification for SjS is the American-European consensus classification criteria for SjS.(Vitali, Bombardieri et al. 2002)

Current understanding about the pathogenesis of SjS stems from the assumption that the autoimmune destruction of the exocrine glands leads to their hypofunction and symptoms of dryness. The existing evidence however does not fully support this assumption and cannot explain the underlying pathogenic mechanisms of SjS for the following reasons: 1) Discordance between severely affected function and abundance of histologically normal and ex vivo functional salivary glands; 2) at least 20% of patients have no evidence of systemic autoimmunity; 3) Animal models of SjS develop glandular dysfunction long before they develop autoimmunity; 4) Dryness and related symptoms respond poorly to immunosuppressive, including newer biologics, but fairly well to secretagogues such as pilocarpine. 5) No pathogenic antibodies or target epitopes have been identified to date to unify the pathogenesis of the syndrome.

All exocrine glands are innervated by the autonomic nervous system (ANS) and dysautonomia can mimic the phenotype of SjS, particularly cardinal manifestations, such as xerostomia and xerophthalmia. Thus we hypothesize that ANS dysfunction is central to the pathogenesis of SjS and propose to systematically study the ANS function in our cohort of patients with primary SjS compared with normative data from age and sex-matched controls. This protocol calls for a comprehensive evaluation of autonomic function, using physiological, neuropharmacologic, neurochemical, and imaging approaches, to identify consistent distinctive patterns of ANS involvement in SjS and thereby improve the diagnosis and understanding of pathophysiologic mechanisms of SjS. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00565526
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date November 26, 2007
Completion date April 10, 2014

See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT06104124 - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3
Recruiting NCT05115487 - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting NCT06437652 - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Recruiting NCT05383677 - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2